Prof Double R

8

Alternative Buyer Research and Acquisition Road Map

Alternative Buyer Recommendation

The list of alternative buyer options includes ten international medical and pharmaceutical companies such as Johnson & Johnson, Pfizer, AbbVie, Novartis, Merck, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Gilead Sciences, and Viatris. Among them, Johnson & Johnson (J&J) is the preferred contingency buyer for the Midwest life sciences organization due to its global presence, diversified healthcare portfolio, financial stability, acquisition-driven growth strategy, and successful integration capabilities.

J&J’s business consists of two main segments: Innovative Medicine and MedTech. The former includes products related to oncology, immunology, neuroscience, and cardiopulmonary, whereas the latter includes cardiovascular, orthopedics’, surgery, and vision. Therefore, the company operates in a broad life sciences and healthcare market, distributing its medical products to hospitals, physicians, clinics, healthcare professionals, and patients. In particular, the company’s 2025 annual report highlights that MedTech’s products are primarily distributed to wholesalers, hospitals, and retailers and utilized mainly by physicians, nurses, hospitals, eye-care professionals, and clinics. (Johnson & Johnson, 2025a)

Therefore, given the wide range of the company’s market coverage and the variety of its healthcare services, Johnson & Johnson is a preferred contingent buyer for the Midwest life sciences company, as the former is able to sell the latter’s products via multiple channels and locations, benefit from the extensive research and development network, and address the needs of affiliated companies. It is noteworthy that the opportunity is especially attractive if the purchased company has products, technology, workforce, intellectual property, and other resources that can be integrated into J&J’s medicine and MedTech divisions.

Financial Situation

J&J’s financial position makes it a reliable buyer with substantial capacity for strategic acquisition. In 2025, worldwide sales reached $94.193 billion, compared with $88.821 billion in 2024, which is 6.0% growth compared to the previous year (Johnson & Johnson, 2026a). Innovative Medicine generated $60.401 billion while MedTech generated $33.792 billion.

In addition, the company reported a significant amount of income before tax for the segment. For example, in 2025, Innovative Medicine generated $22.266 billion and MedTech generated $4.113 billion, and consequently, the segment income before tax reached $26.379 billion (Johnson & Johnson, 2026a). J&J’s 2025 annual report also shows $4.832 billion in additions to property, plant, and equipment and depreciation and amortization of $7.503 billion, representing a significant cash-generating capacity.

The combination of profitability and cash-generating capability is an advantage for the target buyer, as it can provide better financing conditions for the acquisition than a less financially stable company. At the same time, the board must recognize that not every buyer will be right for them. J&J is actively optimizing its portfolio, including acquiring brands, divesting holdings, and a planned separation of its orthopedics business. As a result, there would have to be strategic fit and measurable value shown by the target organization.

Recent Developments

J&J's recent initiatives create the impression of an attractive but selective buyer. In 2025, J&J realized its $3.05 billion acquisition of Halda Therapeutics, adding a clinical-stage oncology platform. The company also completed its acquisition of Intra-Cellular Therapies, with the transaction expected to add approximately $0.7 billion in incremental 2025 sales while generating some near-term earnings dilution (Johnson & Johnson, 2025b). These are significant expenditures that reflect the company's willingness to invest in areas that it thinks will help it grow and thrive.

J&J announced in October 2025 that it would split off its orthopedics’ business, with the expectation of completing the plan within 18 to 24 months. The company felt that such a move would allow it to focus more strategically on its MedTech, particularly about higher growth and higher-margin markets. This is a possible worry as during separation, management's attention and transaction resources could be split (Feldman & Hernandez, 2022). But it also increases J&J's poise as a buyer, since they are taking constructive steps to optimize portfolio and focus their investment on specific growth areas. Moreover, more recently, in June 2026, J&J announced the cash acquisition of Firefly Bio for $1 billion to diversify its oncology pipeline and announced further MedTech innovation, including the introduction of the Shockwave Javelin platform and the Shockwave C2 Aero catheter (Johnson & Johnson, 2026b). These are all indications that the company is interested in strategically aligned transactions and continues to innovate.

Buyer Rationale

Johnson & Johnson is the best option due to several reasons connected to the financial aspect of the acquisition, its focus on innovative technology, recent acquisition activity, and the potential to expand the business beyond its current state. First, J&J had a substantial revenue of $94.2 billion in 2025 with a broad range of businesses (Johnson & Johnson, 2025b), which indicates a certain level of stability. Second, the company’s innovative Medicine and MedTech businesses offer more potential areas of strategic fit. Third, its recent acquisition activity suggests that the management is interested in acquiring products, technologies, and platforms to fuel innovation. Lastly, the company has great potential to help the target organization grow its market beyond its current state.

The primary concern with Johnson & Johnson as the acquirer is the timing, as it tries to balance its acquisition strategy with the pending orthopedics separation. Therefore, the target company should present J&J with a compelling reason to engage in the acquisition given the company’s interest in innovation and focus on other business areas. This will create value for both companies. Overall, J&J’s financial strength, healthcare focus, strategy of continuous innovation, and acquisition activity indicate that it is the best option out of the list of potential acquirers.

Acquisition Road Map

Several of the initial steps in the action plan have been taken since the business development manager joined the strategic planning initiative. The company has already formed the guiding coalition, conducted an industry analysis, examined the alternative buyers, and created a shortlist. The current contingency step is assessing and selecting the preferred alternative buyer, with Johnson & Johnson being recommended for the next stage. All of the abovementioned preliminary stages should be presented to the board since they show that the company has progressed by preparing a contingency plan to ensure that the original deal’s failure does not impede the organization objective to move forward with the plan.

Over the next 18 to 24 months, the process should move through buyer outreach, preliminary valuation, due diligence, negotiation, approvals, and integration. The first two months should focus on confidential outreach and a nondisclosure agreement. Months 5–6 should cover preliminary valuation and strategic-fit review. Months 7–10 should be devoted to financial, legal, human-resource, regulatory, commercial, intellectual-property, and operational due diligence. Months 11–12 should focus on a letter of intent and transaction structure. Months 13–16 should cover definitive agreements, financing, regulatory and board approvals. Finally, months 17–22 should focus on integration planning, employee communication, systems transition and closing. The remaining months through month 24 should be reserved for final integration, stabilization and contingency management.

Responsibility should be shared across the guiding coalition. Business development should lead to buyer communication and deal coordination. Finance should lead to valuation and financial diligence. Legal should manage confidentiality, contracts, regulatory requirements, and transaction documents. Human resources should address employee retention, benefits, organizational design, and communications. Operations and information technology should prepare for process and systems integration. Senior leadership and the board should provide approval at major decision gates. Each phase depends on the previous phase producing sufficient evidence to proceed.

Gantt Chart

The completed Gantt chart below translates the road map into a timeline. Completed work is shown at 100%, in-process work is shown at partial completion, and future work is shown at 0%. The schedule covers the first 24 months of the contingency acquisition process.

Conclusion

Johnson & Johnson is the best option as a contingent buyer for Midwest life sciences organization because of the company’s financial stability, wide reach in the market, and willingness to acquire other companies. Although the orthopedics division’s separation from J&J may create challenges for the company in terms of timing and resources management, the overall benefits of such an acquisition would be substantial for both companies. J&J’s strong financial performance, cash generation capacity, and innovation in Innovative Medicine and MedTech areas make the company a preferred choice for acquisition. Following the 24-month road map for the acquisition will help the company avoid some of the challenges that may arise during and after the deal.

References

Feldman, E. R., & Hernandez, E. (2022). Synergy in mergers and acquisitions: Typology, life cycles, and value.  Academy of Management Review,  47(4), 549-578.

Johnson & Johnson. (2025a). 2025 annual report. https://www.jnj.com/download/johnson-johnson-2025-annual-report

Johnson & Johnson. (2025b). Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies. https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies

Johnson & Johnson. (2026a). Johnson & Johnson reports fourth-quarter and full-year 2025 results. https://www.jnj.com/

Johnson & Johnson. (2026b). Johnson & Johnson to acquire Firefly Bio, Inc. to expand oncology pipeline with novel degrader antibody conjugate platform. https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-to-Acquire-Firefly-Bio-Inc--to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-Platform/default.aspx